Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Study Information
Alliance Study ID: N1031
NCT Study ID (ClinicalTrials.gov): NCT01086605
Alliance Committee: Breast Cancer
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Alvaro Moreno-Asptia, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy, such as pixantrone dimaleate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pixantrone dimaleate in different ways may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well pixantrone dimaleate works in treating patients with HER2-negative metastatic breast cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information